• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . US National Institutes of Health Prioritization of SARS-CoV-2 Variants

tetano

Editor, Senior Moderator
Emerg Infect Dis


. 2023 Apr 13;29(5).
doi: 10.3201/eid2905.221646. Online ahead of print.
US National Institutes of Health Prioritization of SARS-CoV-2 Variants

Sam Turner, Arghavan Alisoltani, Debbie Bratt, Liel Cohen-Lavi, Bethany L Dearlove, Christian Drosten, Will M Fischer, Ron A M Fouchier, Ana Silvia Gonzalez-Reiche, Lukasz Jaroszewski, Zain Khalil, Eric LeGresley, Marc Johnson, Terry C Jones, Barbara Mühlemann, David O'Connor, Mayya Sedova, Maulik Shukla, James Theiler, Zachary S Wallace, Hyejin Yoon, Yun Zhang, Harm van Bakel, Marciela M Degrace, Elodie Ghedin, Adam Godzik, Tomer Hertz, Bette Korber, Jacob Lemieux, Anna M Niewiadomska, Diane J Post, Morgane Rolland, Richard Scheuermann, Derek J Smith

Abstract

Since late 2020, SARS-CoV-2 variants have regularly emerged with competitive and phenotypic differences from previously circulating strains, sometimes with the potential to escape from immunity produced by prior exposure and infection. The Early Detection group is one of the constituent groups of the US National Institutes of Health National Institute of Allergy and Infectious Diseases SARS-CoV-2 Assessment of Viral Evolution program. The group uses bioinformatic methods to monitor the emergence, spread, and potential phenotypic properties of emerging and circulating strains to identify the most relevant variants for experimental groups within the program to phenotypically characterize. Since April 2021, the group has prioritized variants monthly. Prioritization successes include rapidly identifying most major variants of SARS-CoV-2 and providing experimental groups within the National Institutes of Health program easy access to regularly updated information on the recent evolution and epidemiology of SARS-CoV-2 that can be used to guide phenotypic investigations.

Keywords: 2019 novel coronavirus disease; COVID-19; SARS-CoV-2; SARS-CoV-2 variants; US National Institute of Allergy and Infectious Diseases; US National Institutes of Health; computational biology; coronavirus disease; epidemiological monitoring; epidemiology; pandemic prevention and control; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
 
Back
Top Bottom